Prognostic Factors in Patients With STEMI Treated by pPCI

  • STATUS
    Recruiting
  • days left to enroll
    34
  • participants needed
    5000
  • sponsor
    Renmin Hospital of Wuhan University
Updated on 8 November 2021
stemi
percutaneous coronary intervention

Summary

Prognostic Factors in patients with STEMI Treated by pPCI is a retrospective observational study in China.This study aims to identify the main prognostic factors to recognize patients with increased major adverse cardiovascular events risks and conduct a further intervention for these patients. The study will provide clinical, functional, and invasive treatment measures with systematic serial sampling and evaluation. Moreover, the knowledge on the prognostic factors of STEMI patients treated by primary percutaneous coronary intervention will be increased.

Description

Currently, primary percutaneous coronary intervention is the first choice for patients with acute ST-segment elevation myocardial infarction. In the past 40 years, the development of rapid reperfusion therapy has gradually reduced the mortality rate of cardiovascular disease. Compared with drug thrombolysis therapy, pPCI can effectively improve epicardial blood flow reperfusion, reduce infarct size and improve survival rate.

However, although epicardial blood flow reperfusion in patients with STEMI can be improved by pPCI, the short-term and long-term major adverse cardiovascular events (MACE) in patients with STEMI caused by ischemia-reperfusion injury, no-reflow phenomenon, microvascular obstruction, and delayed microvascular perfusion are still worrying. Clinical studies have reported that mechanical hemodynamic support device is not satisfactory for STEMI patients who still develop circulatory failure after pPCI treatment, and it may only have a better effect on high-risk patients. Clinical studies reported that the incidence of in-hospital congestive heart failure in STEMI patients treated with pPCI was 6%. One retrospective study of 251079 patients with STEMI by Wu et al showed that the in-hospital mortality rate of STEMI patients could be as high as 9.2%. However, there are no reliable scoring criteria to evaluate the incidence of acute congestive heart failure after pPCI in patients with STEMI.

As STEMI patients are often complicated with hypertension, hypercholesterolemia, diabetes, and other risk factors, each patient may face a different situation and more personalized assessment criteria are needed to deal with complex clinical problems, especially for those at high risk. We are committed to developing a prediction model to predict the risk of in-hospital acute heart failure in STEMI patients treated with pPCI, to adjust the diagnosis and treatment plan for those medium-and high-risk patients.

Details
Condition Myocardial Infarction, STEMI, ST Segment Elevation Myocardial Infarction
Treatment No intervention
Clinical Study IdentifierNCT04996901
SponsorRenmin Hospital of Wuhan University
Last Modified on8 November 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Age18
ST-segment elevation myocardial infarction was defined according to the universal definition of myocardial infarction

Exclusion Criteria

Patient with heart failure in admission
STEMI with symptom-onset-to-balloon time>24h
pPCI was not successful
Patients were complicated with congenital heart disease, valvular heart disease, severe chronic obstructive pulmonary disease, malignant tumor, multiple organ failure in admission
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note